

## PHARMACY PRE-AUTHORIZATION CRITERIA



<b>DRUG</b>	Rexulti (brexipiprazole)
<b>POLICY #</b>	11137
<b>INDICATIONS</b>	Rexulti is indicated for: <ol style="list-style-type: none"><li>1. The treatment of schizophrenia</li><li>2. The adjunctive treatment to antidepressants for the treatment of major depressive disorder (MDD)</li></ol>
<b>CRITERIA</b>	<p><b><u>Criteria for the diagnosis of Major Depressive Disorder:</u></b></p> <p>Rexulti is covered for depression and related conditions only if there is:</p> <ol style="list-style-type: none"><li>1) Failure or intolerance to at least two (2) first line agents listed below <b>AND</b></li><li>2) Concurrent use of an antidepressant <b>AND</b></li><li>3) Failure of Abilify when tried in combination with an antidepressant <b>OR</b></li><li>4) Patient has taken Rexulti at any time in the past with success and discontinued use. They may then receive authorization to restart.</li></ol> <p><b><u>First-line agents:</u></b></p> <p><b>Any of the 6 SSRI's:</b> citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, escitalopram</p> <p><b>Any of the 6 SNRI's:</b> Cymbalta, Pristiq, venlafaxine ER, Desvenlafaxine Fumarate, Fetzima, Khedezla</p> <p><b>Other antidepressants:</b> Viibryd, bupropion, Trintellix</p> <p><b><u>Criteria for the diagnosis of Schizophrenia:</u></b></p> <p>Rexulti is covered for the treatment of Schizophrenia when the following criteria is met:</p> <ol style="list-style-type: none"><li>1) Clinical diagnosis made by a psychiatrist <b>AND</b></li><li>2) Failure or intolerance to any one of the 6 generic atypical antipsychotics: aripiprazole, quetiapine, ziprasidone, risperidone, olanzapine or clozapine <b>OR</b></li><li>3) Patient has taken Rexulti at any time in the past with success and discontinued use. They may then receive authorization to restart.</li></ol>

## PHARMACY PRE-AUTHORIZATION CRITERIA

<b>DRUG</b>	Rexulti (brexipiprazole)
<b>LIMITATIONS</b>	<ul style="list-style-type: none"> <li>• If the above criteria are met initial authorization will be given for 1 year</li> <li>• A current progress note must be submitted for reauthorization</li> </ul>
<b>REFERENCES</b>	<ol style="list-style-type: none"> <li>1. Facts &amp; Comparisons online</li> <li>2. Rexulti package insert, Otsuka Pharmaceuticals, Tokyo, Japan</li> </ol>
<b>P&amp;T REVIEW HISTORY</b>	11/15, 5/16, 2/17, 1/18
<b>REVISION RECORD</b>	2/16